Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants undergoing microsurgical testicular sperm extraction.~* Participants over 18 years of age who can provide informed consent~* Participants with no contraindication to the consumption gabapentin or documented allergy/intolerance~* Participants not currently using opiates for another reason~Exclusion Criteria:~* Contraindication to the consumption of celecoxib or gabapentin~* History of substance abuse (including prior opiate abuse)~* Narcotic use within last 3 months~* Any of the following comorbidities: renal failure, heart disease, peptic ulcer disease, cerebrovascular disease, significant liver disease, untreated depression, chronic pain disorder, or bleeding diatheses~* Medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this trial, or constitutes an unacceptable risk to the subject

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).